Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA.

ViiV Healthcare UK (No. 4) Ltd., a subsidiary of GSK Plc, is a company headquartered in Middlesex, UK, that engages in development, enhancement, maintenance, protection and exploitation of intellectual property assets. It was founded in 2015.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Microbiotix, Inc. is an American private company located in Worcester, MA, involved in pharmaceutical preparations. The firm was founded by Wendy E. Rieder.\nOn its website, the company says this about itself: Microbiotix is a Worcester, MA-based biotech company focused on the discovery and development of novel drugs that target serious infectious diseases and multi-drug resistant pathogens. The Company's lead program, MBX-400, a novel, potent nucleoside dual DNA polymerase/kinase inhibitor for the management of cytomegalovirus (CMV) disease in transplant patients, is Phase 2-ready.

Aicuris Anti-Infective Cures AG is a German company located in Wuppertal that engages in research and development in natural sciences, engineering, agricultural sciences and medicines. It was founded in 2006 by Helga R��bsamen-Schaeff. Holger Zimmermann is currently the CEO of the firm.

Develops products for the treatment of human immune systems disorders and diseases

iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated.\nThe company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take.\nTheir innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus.

Kunming Institute of Zoology (KIZ) (中国科学院昆明动物研究所), one of the 20 biological institutes under the Chinese Academy of Sciences (CAS), is one of China's first class zoological research institutes, located in Kunming, Yunnan province. The Institute has access to the unique and diversified animal resources of the Eastern Himalayas as well as a wide variety of the species from across Southeast Asia, the southern parts of Yunnan province being part of the Indo-Burma biodiversity hotspot. KIZ focuses on life science research, with research groups including systematic zoology, conservation biology, cytology, molecular biology, genome evolution, reproductive and developmental biology, neurobiology, immunological biology on important virus disease, zoological toxicology and primate biology.

Toyo Sugar Refining Co., Ltd. engages in the refining and sale of sugar. It operates through the following segments: Sugar, Functional Ingredients, and Others. The Sugar segment covers the refining and selling of sugar. The Functional Ingredients segment offers alphaG Sweets, alphaG Rutin, alphaG Hesperidin, C-mo 2G, Baobab Sariche, Citron Polyphenol, and alphaG Soy Isoflavone. The Others segment manufactures and sells in-house developed oligonol and perilla leaf extracts. The company was founded on November 29, 1949 and is headquartered in Tokyo, Japan.

Part of Lantheus Holdings, Inc., Progenics Pharmaceuticals Nevada, Inc. is a company headquartered in the United States that manufactures pharmaceutical products.

Selva Therapeutics, Inc. is an American private company located in Del Mar, CA, that operates as a biotechnology company dedicated to development of therapeutics for infectious diseases. It was founded by Felix Wilhelm Frueh and Thomas E. Daley. Thomas E. Daley is currently the CEO of the firm.\nThe company says this about itself: Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. By rapidly developing SLV213 for COVID-19, Selva Therapeutics intends to bring a valuable treatment to the market that has the potential to fight multiple life-threatening infectious diseases.

Urban GmbH & Co. KG is a German private company located in Wuesting that manufactures agricultural and forestry machinery.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Alla Chem LLC is a company headquartered in Hallandale Beach, FL, involved in pharmaceutical preparations. It was founded in 2004.